A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drug

Joshi, Jayashree; Joshi, Usha; Sankolli, G. M.; Gupta, Kriti; Rao, Adupa P.; Hazari, K.; Sheth, U K; Saxena, B.N.

doi:10.1016/0010-7824(80)90034-7

Cited by 33 publications

(22 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three studies addressed COC hormone PK with rifampin, and all demonstrated reductions in estrogen and/or progestin exposure . A single‐sequence crossover study of eight women on chronic rifampin therapy for tuberculosis reported ethinyl estradiol (EE) and NET PK after a single COC pill during and after rifampin therapy .…”

Section: Resultsmentioning

confidence: 99%

Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review

Simmons

Haddad

Nanda

et al. 2017

BJOG

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review

Simmons

Haddad

Nanda

et al. 2017

BJOG

View full text Add to dashboard Cite

show abstract

“…Although all patients showed good evidence of microsomal enzyme induction, interindividual differences in the response to rifampicin were observed. Joshi et al (1980) also noted that of 9 women treated with a low-dose combination oral contraceptive and rifampicin 8 to 10 mg/kg, 3 experienced menstrual irregularities while 2 showed a premenstrual rise of plasma progesterone levels. Both plasma concentrations and AVC for norethisterone declined significantly.…”

Section: Oral Contraceptivesmentioning

confidence: 94%

Pharmacokinetic Drug Interactions with Rifampicin

Venkatesan

1992

Clinical Pharmacokinetics

124

View full text Add to dashboard Cite

Rifampicin, an antituberculosis drug, is usually administered for 4 to 12 months with other antituberculosis drugs or medications from other classes. A potential for drug interactions often exists because rifampicin is a potent inducer of hepatic drug metabolism, as evidenced by a proliferation of smooth endoplasmic reticulum and an increase in the cytochrome P450 content in the liver. The induction is a highly selective process and not every drug metabolised via oxidation is affected. Case reports and studies have demonstrated enhanced metabolism of several drugs; most of these interactions are clinically important. At the start of rifampicin treatment, and again at the end, clinicians must check the dosages of any accompanying medications with which rifampicin may potentially interact. Monitoring of clinical response and blood drug concentrations is essential to adjust the drug dosage during rifampicin therapy. Rifampicin also interacts with cholephils such as bilirubin and bromosulphthalein. Its pharmacokinetics are reported to be altered by ethambutol, p-aminosalicylic acid (through its excipient component), ketoconazole, cyclosporin, clofazimine, probenecid and phenobarbital through one or other of the following mechanisms--impaired absorption of rifampicin, competition between the drug and rifampicin for hepatic uptake and altered hepatic metabolism of rifampicin. Most interactions affecting rifampicin have been relatively minor or are not expected to alter its therapeutic efficacy.

show abstract

“…Using the rifampicin studies to illustrate this, the two earlier studies both showed ovulation in some women, 4,5 whereas the two later studies showed no ovulation. 6,7 However, the two earlier studies gave rifampicin for longer (21 days or more) than the later two (10 and 14 days).…”

Section: Studies Assessing Ovulation Parametersmentioning

confidence: 99%

Drug interactions and hormonal contraception

Lee

2009

Trends Urology, Gynecol. Sexual Health

View full text Add to dashboard Cite

Predicting drug interactionsGone are the days when drug interactions were picked up only retrospectively, after a medicine was in widespread clinical use. With increasing understanding of drug metabolism and interaction mechanisms, studies are now carried out before a new medicine is approved. From these, a reasonable prediction can usually be made about how likely it is that the new medicine will interact with established drugs, especially for those interactions occurring via the cytochrome P450 (CYP) isoenzyme system of drug metabolism. Nevertheless, some mechanisms of metabolism are less well understood (eg glucuronidation), and unexpected interactions sometimes occur, so we still need to be alert to the possibility of a drug interaction when events are unforeseen.

show abstract

A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drug

Cited by 33 publications

References 9 publications

Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review

Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review

Pharmacokinetic Drug Interactions with Rifampicin

Drug interactions and hormonal contraception

Contact Info

Product

Resources

About